Marie Morfouace
Overview
Explore the profile of Marie Morfouace including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tagliamento M, Morfouace M, Loizides C, Oliveira J, Greillier L, Raimbourg J, et al.
NPJ Precis Oncol
. 2024 Feb;
8(1):37.
PMID: 38366021
Arcagen (NCT02834884) is a European prospective study aiming at defining the molecular landscape of rare cancers for treatment guidance. We present data from the cohort of rare thoracic tumors. Patients...
2.
Morfouace M, Horak P, Kreutzfeldt S, Stevovic A, de Rojas T, Denisova E, et al.
Eur J Cancer
. 2022 Dec;
178:216-226.
PMID: 36470093
Background: Adolescent and young adult (AYA) patients with cancer are poorly recruited to molecularly targeted trials and have not witnessed the advances in cancer treatment and survival seen in other...
3.
Galot R, Le Tourneau C, Saada-Bouzid E, Daste A, Even C, Debruyne P, et al.
Eur J Cancer
. 2021 Oct;
158:17-26.
PMID: 34638090
Purpose: Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group 2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human leukocyte antigen E...
4.
Hodroj K, Stevovic A, Attignon V, Ferraioli D, Meeus P, Croce S, et al.
Cancers (Basel)
. 2021 Jan;
13(2).
PMID: 33435376
Most patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse...
5.
Morfouace M, Stevovic A, Vinches M, Golfinopoulos V, Jin D, Holmes O, et al.
ESMO Open
. 2020 Dec;
5(6):e001075.
PMID: 33262201
Purpose: Rare cancers are defined by an incidence of <6 out of 100 000 cases per year. They are under-represented in clinical research including tumour molecular analysis. The aim of...
6.
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer
Slavish P, Chi L, Yun M, Tsurkan L, Martinez N, Jonchere B, et al.
Cancer Res
. 2020 Jul;
80(17):3507-3518.
PMID: 32651255
Inhibition of members of the bromodomain and extraterminal (BET) family of proteins has proven a valid strategy for cancer chemotherapy. All BET identified to date contain two bromodomains (BD; BD1...
7.
Hoogstrate Y, Vallentgoed W, Kros J, de Heer I, de Wit M, Eoli M, et al.
Neurooncol Adv
. 2020 Jul;
2(1):vdz051.
PMID: 32642719
Background: The randomized phase II INTELLANCE-2/EORTC_1410 trial on EGFR-amplified recurrent glioblastomas showed a trend towards improved overall survival when patients were treated with depatux-m plus temozolomide compared with the control...
8.
de Rojas T, Kasper B, van der Graaf W, Pfister S, Bielle F, Ribalta T, et al.
Int J Cancer
. 2019 Aug;
147(4):1180-1184.
PMID: 31465545
For most adolescent and young adult (AYA) cancers, age-specific molecular features are poorly understood. EORTC-SPECTA, an academic translational research infrastructure for biomaterial collection, will explicitly recruit AYA patients and will...
9.
French P, Eoli M, Sepulveda J, de Heer I, Kros J, Walenkamp A, et al.
Neuro Oncol
. 2019 May;
21(10):1263-1272.
PMID: 31125418
Background: Precision medicine trials targeting the epidermal growth factor receptor (EGFR) in glioblastoma patients require selection for EGFR-amplified tumors. However, there is currently no gold standard in determining the amplification...
10.
Teitz T, Fang J, Goktug A, Bonga J, Diao S, Hazlitt R, et al.
J Exp Med
. 2018 Mar;
215(4):1187-1203.
PMID: 29514916
Hearing loss caused by aging, noise, cisplatin toxicity, or other insults affects 360 million people worldwide, but there are no Food and Drug Administration-approved drugs to prevent or treat it....